MCA
HRMY icon

McGuire Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

McGuire Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$7K – 938
2026
Q1 		$7K Hold
250
– – ﹤0.01% 463
2025
Q4 		$9.36K Buy
+250
New +$8.22K 0.01% 424

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

McGuire Capital Advisors's HRMY Position: Q2 2026 in Review

McGuire Capital Advisors sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 250 shares — an estimated $7K sold.

McGuire Capital Advisors first reported a position in HRMY in Q4 2025 and held it in 2 quarters. The position peaked at $9.36K in Q4 2025. 325 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • McGuire Capital Advisors reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • McGuire Capital Advisors sold 250 Harmony Biosciences shares in Q2 2026, an estimated $7K.
  • McGuire Capital Advisors first reported a position in Harmony Biosciences in Q4 2025 and held it in 2 quarters.
  • McGuire Capital Advisors's Harmony Biosciences position peaked at $9.36K in Q4 2025.
  • 325 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.